Adriana Ribeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adriana Ribeiro has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Helena Cabral-Marques
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal
4 shared publications Helena Cabral-Marques
3 shared publications- Olga Silva
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal
3 shared publications - Rita Serrano
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal
3 shared publications Daniele Oliveira
Department of Pharmacy, Pharmacology and Health Technologies, Research Institute for Medicine, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
2 shared publications- Daniele Oliveira
Ophthalmologist, Centro Hospitalar de Setúbal and Hospital da Luz Setúbal, 2900-722 Setúbal, Portugal
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Clusterar Unipessoal LDA
- p. 1-37
Macrocycle and Polymer-Based Drug Delivery Systems of Cannabinoids from Cannabis sativa L.: A Systematic Review
This systematic review underscores the transformative potential of cyclodextrins (CDs) and polymers in enhancing cannabinoid delivery systems. Analyzing 55 eligible studies from an initial pool of 221 articles, we revealed significant advancements in the solubility, stability, and bioavailability of cannabinoids through complexation with CDs. Chemically modified CDs, such as RM-β-CD and HP-β-CD, exhibited superior performance, optimizing the pharmacokinetics of cannabinoids like Δ9-THC and CBD by improving drug stability, solubility, and therapeutic efficacy. The review highlighted promising applications in anticancer, antimicrobial, and CNS-targeted therapies, demonstrating increased cytotoxicity against cancer cells and enhanced wound healing capabilities. CDs also showed potential in ocular and topical applications, enhancing solubility and permeability for conditions like glaucoma. Despite the predominance of CDs due to their well-established benefits and cost-effectiveness, the review identified a need for further exploration of other macrocycles, such as cucurbiturils and calixarenes, in cannabinoid delivery. Overall, this review emphasizes the pivotal role of CDs and polymers in addressing solubility challenges associated with poorly water-soluble drugs, advocating for continued research to expand their clinical applications and improve therapeutic outcomes across various medical contexts.
- 1 January 2026
- Published by Clusterar Unipessoal LDA
- p. 1-37
Open AccessMacrocycle and Polymer-Based Drug Delivery Systems of Cannabinoids from Cannabis sativa L.: A Systematic Review
This systematic review underscores the transformative potential of cyclodextrins (CDs) and polymers in enhancing cannabinoid delivery systems. Analyzing 55 eligible studies from an initial pool of 221 articles, we revealed significant advancements in the solubility, stability, and bioavailability of cannabinoids through complexation with CDs. Chemically modified CDs, such as RM-β-CD and HP-β-CD, exhibited superior performance, optimizing the pharmacokinetics of cannabinoids like Δ9-THC and CBD by improving drug stability, solubility, and therapeutic efficacy. The review highlighted promising applications in anticancer, antimicrobial, and CNS-targeted therapies, demonstrating increased cytotoxicity against cancer cells and enhanced wound healing capabilities. CDs also showed potential in ocular and topical applications, enhancing solubility and permeability for conditions like glaucoma. Despite the predominance of CDs due to their well-established benefits and cost-effectiveness, the review identified a need for further exploration of other macrocycles, such as cucurbiturils and calixarenes, in cannabinoid delivery. Overall, this review emphasizes the pivotal role of CDs and polymers in addressing solubility challenges associated with poorly water-soluble drugs, advocating for continued research to expand their clinical applications and improve therapeutic outcomes across various medical contexts.
- Top Cited PapersOpen Access
Curcumin in Ophthalmology: Mechanisms, Challenges, and Emerging Opportunities
Ocular diseases affecting the anterior and posterior segments of the eye are major causes of global vision impairment. Curcumin, a natural polyphenol, exhibits anti-inflammatory, antioxidant, antibacterial, and neuroprotective properties, making it a promising candidate for ocular therapy. However, its clinical use is hindered by low aqueous solubility, poor bioavailability, and rapid systemic elimination. This review comprehensively highlights advances in curcumin delivery systems aimed at overcoming these challenges. Emerging platforms, including proniosomal gels, transferosomes, and cyclodextrin complexes, have improved solubility, permeability, and ocular retention. Nanoparticle-based carriers, such as hybrid hydrogels and biodegradable nanoparticles, enable sustained release and targeted delivery, supporting treatments for posterior segment diseases like diabetic retinopathy and age-related macular degeneration. For anterior segment conditions, including keratitis and dry eye syndrome, cyclodextrin-based complexes and mucoadhesive systems enhance corneal permeability and drug retention. Mechanistically, curcumin modulates key pathways, such as NF-κB and TLR4, reducing oxidative stress, angiogenesis, and apoptosis. Emerging strategies like photodynamic therapy and neuroprotective approaches broaden their application to eyelid conditions and neuroinflammatory ocular diseases. These advancements address curcumin’s pharmacokinetic limitations, supporting its clinical translation into ophthalmic therapies. This work underscores curcumin’s potential in ocular disease management and advocates clinical trials to validate its safety, efficacy, and therapeutic relevance.
Top Cited PapersOpen AccessCurcumin in Ophthalmology: Mechanisms, Challenges, and Emerging Opportunities
Ocular diseases affecting the anterior and posterior segments of the eye are major causes of global vision impairment. Curcumin, a natural polyphenol, exhibits anti-inflammatory, antioxidant, antibacterial, and neuroprotective properties, making it a promising candidate for ocular therapy. However, its clinical use is hindered by low aqueous solubility, poor bioavailability, and rapid systemic elimination. This review comprehensively highlights advances in curcumin delivery systems aimed at overcoming these challenges. Emerging platforms, including proniosomal gels, transferosomes, and cyclodextrin complexes, have improved solubility, permeability, and ocular retention. Nanoparticle-based carriers, such as hybrid hydrogels and biodegradable nanoparticles, enable sustained release and targeted delivery, supporting treatments for posterior segment diseases like diabetic retinopathy and age-related macular degeneration. For anterior segment conditions, including keratitis and dry eye syndrome, cyclodextrin-based complexes and mucoadhesive systems enhance corneal permeability and drug retention. Mechanistically, curcumin modulates key pathways, such as NF-κB and TLR4, reducing oxidative stress, angiogenesis, and apoptosis. Emerging strategies like photodynamic therapy and neuroprotective approaches broaden their application to eyelid conditions and neuroinflammatory ocular diseases. These advancements address curcumin’s pharmacokinetic limitations, supporting its clinical translation into ophthalmic therapies. This work underscores curcumin’s potential in ocular disease management and advocates clinical trials to validate its safety, efficacy, and therapeutic relevance.
- Open Access
Polyelectrolytes and Polyelectrolyte Complexes as Future Antibacterial Agents
Antibiotic-resistance (ABR) poses a critical public health challenge within the broader antimicrobial resistance crisis. This review evaluates the potential of polyelectrolytes (PEs) and polyelectrolyte complexes (PECs) for controlled antibiotic delivery as a strategy to combat ABR and biofilm-related infections. PECs, particularly those incorporating chitosan and other polycations, enhance antibacterial efficacy by disrupting bacterial cell walls and obstructing their nutrient flow. They are also effective in penetrating biofilms and providing sustained drug release. Despite these advantages, there is a need for further in vivo research and clinical trials to validate these findings. This review provides a comprehensive overview of PECs’ potential to advance antibacterial therapies and outlines future research directions to further explore their applications.
Open AccessPolyelectrolytes and Polyelectrolyte Complexes as Future Antibacterial Agents
Antibiotic-resistance (ABR) poses a critical public health challenge within the broader antimicrobial resistance crisis. This review evaluates the potential of polyelectrolytes (PEs) and polyelectrolyte complexes (PECs) for controlled antibiotic delivery as a strategy to combat ABR and biofilm-related infections. PECs, particularly those incorporating chitosan and other polycations, enhance antibacterial efficacy by disrupting bacterial cell walls and obstructing their nutrient flow. They are also effective in penetrating biofilms and providing sustained drug release. Despite these advantages, there is a need for further in vivo research and clinical trials to validate these findings. This review provides a comprehensive overview of PECs’ potential to advance antibacterial therapies and outlines future research directions to further explore their applications.
- Open Access
Enhancing Cannabinoid Bioavailability in Pain Management: The Role of Cyclodextrins
Chronic pain (CP), including pain related to cancer, affects approximately 2 billion people worldwide, significantly diminishing quality of life and imposing socio-economic burdens. Current treatments often provide limited relief and may cause adverse effects, demanding more effective alternatives. Natural compounds from Cannabis sativa L., particularly cannabinoids like THC and CBD, exhibit analgesic and anti-inflammatory properties, but their therapeutic use is restricted by poor solubility and low bioavailability. Cyclodextrins (CDs) and cyclic oligosaccharides may encapsulate hydrophobic drugs in order to enhance their solubility and stability, offering a promising solution to these challenges. This study explores the formation of CD inclusion complexes with cannabinoids and specific terpenes, such as D-limonene (LIM), beta-caryophyllene (BCP), and gamma-terpinene (γ-TPN), aiming to improve pharmacokinetic profiles and therapeutic efficacy. We discuss analytical techniques for characterizing these complexes and their mechanisms of action, highlighting the potential of CDs to optimize drug formulations. The integration of CDs in cannabinoid therapies may enhance patient compliance and treatment outcomes in CP management. Future research should focus on innovative formulations and delivery systems to maximize the clinical applications of those compounds.
Open AccessEnhancing Cannabinoid Bioavailability in Pain Management: The Role of Cyclodextrins
Chronic pain (CP), including pain related to cancer, affects approximately 2 billion people worldwide, significantly diminishing quality of life and imposing socio-economic burdens. Current treatments often provide limited relief and may cause adverse effects, demanding more effective alternatives. Natural compounds from Cannabis sativa L., particularly cannabinoids like THC and CBD, exhibit analgesic and anti-inflammatory properties, but their therapeutic use is restricted by poor solubility and low bioavailability. Cyclodextrins (CDs) and cyclic oligosaccharides may encapsulate hydrophobic drugs in order to enhance their solubility and stability, offering a promising solution to these challenges. This study explores the formation of CD inclusion complexes with cannabinoids and specific terpenes, such as D-limonene (LIM), beta-caryophyllene (BCP), and gamma-terpinene (γ-TPN), aiming to improve pharmacokinetic profiles and therapeutic efficacy. We discuss analytical techniques for characterizing these complexes and their mechanisms of action, highlighting the potential of CDs to optimize drug formulations. The integration of CDs in cannabinoid therapies may enhance patient compliance and treatment outcomes in CP management. Future research should focus on innovative formulations and delivery systems to maximize the clinical applications of those compounds.
- Open Access
- 9 September 2024
- Published by MDPI AG in Future Pharmacology
- Vol. 4 (3) , 590-625
Cannabinoids from C. sativa L.: Systematic Review on Potential Pharmacological Effects against Infectious Diseases Downstream and Multidrug-Resistant Pathogens
Cannabis sativa L. has garnered attention as a potential source for new antimicrobial agents, particularly due to the increased prevalence of microbial resistance to conventional antimicrobials and the emergence of multidrug-resistant pathogens. This review, conducted according to the PRISMA 2020 statement, systematically analyzed the antimicrobial properties of C. sativa extracts and cannabinoids against various bacteria, fungi, viruses, and parasites. Data were collected from the scientific literature (102 papers) and clinical trials (5 studies) from 2014 to June 2024. Findings revealed that cannabinoids, especially CBD, demonstrate significant antimicrobial activity against Gram-positive bacteria like MRSA, Gram-negative bacteria such as Pseudomonas aeruginosa, various Candida species, SARS-CoV-2, and HIV. Additionally, CBD showed efficacy against parasitic infections like Echinococcus granulosus and Leishmania species. These results suggest that cannabinoids may represent a new class of antimicrobial agents with unique and diverse mechanisms of action, potentially effective in broad-spectrum therapies. This study highlights the urgent need for further research and standardized clinical trials to validate these findings and to develop cannabinoid-based treatments. The antimicrobial properties of C. sativa align with WHO priorities and support global health initiatives, offering promising avenues for addressing antimicrobial resistance and improving public health outcomes.
- 9 September 2024
- Published by MDPI AG in Future Pharmacology
- Vol. 4 (3) , 590-625
Open AccessCannabinoids from C. sativa L.: Systematic Review on Potential Pharmacological Effects against Infectious Diseases Downstream and Multidrug-Resistant Pathogens
Cannabis sativa L. has garnered attention as a potential source for new antimicrobial agents, particularly due to the increased prevalence of microbial resistance to conventional antimicrobials and the emergence of multidrug-resistant pathogens. This review, conducted according to the PRISMA 2020 statement, systematically analyzed the antimicrobial properties of C. sativa extracts and cannabinoids against various bacteria, fungi, viruses, and parasites. Data were collected from the scientific literature (102 papers) and clinical trials (5 studies) from 2014 to June 2024. Findings revealed that cannabinoids, especially CBD, demonstrate significant antimicrobial activity against Gram-positive bacteria like MRSA, Gram-negative bacteria such as Pseudomonas aeruginosa, various Candida species, SARS-CoV-2, and HIV. Additionally, CBD showed efficacy against parasitic infections like Echinococcus granulosus and Leishmania species. These results suggest that cannabinoids may represent a new class of antimicrobial agents with unique and diverse mechanisms of action, potentially effective in broad-spectrum therapies. This study highlights the urgent need for further research and standardized clinical trials to validate these findings and to develop cannabinoid-based treatments. The antimicrobial properties of C. sativa align with WHO priorities and support global health initiatives, offering promising avenues for addressing antimicrobial resistance and improving public health outcomes.
- 1 January 2024
- Published by Medknow in The Pan-American Journal of Ophthalmology
- Vol. 6 (1)
Incidence of malignant eyelid tumors: A 6-year period review (2015–2021)
Background: Basal cell carcinoma (BCC), the most common malignant tumor, accounts for 85%–95% of cases of eyelid malignant tumors. Demographic factors such as age, gender, tumor location, and subtype play a crucial role in epidemiological knowledge. We investigated eyelid BCC diagnosis and treatment at the Department of Ophthalmology in Centro Hospitalar de Setúbal (CHS). Methods: A retrospective study was conducted on patient cases with suspected eyelid epithelial tumors who underwent excisional biopsy surgery. The study included data from the CHS database between 2015 and 2021. Data collection and subsequent analysis were based on histopathological results. Results: In our study, were analyzed a total of 47 tumor cases, with 68.1% located on the lower eyelids and 31.9% on the upper eyelids. Among these cases, 25 (53.2%) were classified as benign, while 22 (46.8%) were identified as malignant eyelid tumors. BCCs accounted for 90.9% of all malignant cases, with an average age of 71.7 ± 16.6 years. The nodular subtype was the most prevalent, followed by infiltrative and superficial subtypes. Superficial BCC patients were older than infiltrative BCC patients (median age = 69.5 years vs. 61.5 years). BCC primarily affected the lower eyelids compared to the upper eyelid, and there was a slight female predominance (n = 11). All diagnosed BCCs correlated with sun-exposed regions. Conclusions: Timely intervention is crucial for reducing morbidity. These findings emphasize the need for improved registration and notification systems to enhance the prevention and treatment of eyelid BCCs. Furthermore, despite advancements in ultraviolet-blocking technologies, further development of sunscreen specifically formulated for ocular use remains necessary to reduce the incidence of eyelid tumors.
- 1 January 2024
- Published by Medknow in The Pan-American Journal of Ophthalmology
- Vol. 6 (1)
Incidence of malignant eyelid tumors: A 6-year period review (2015–2021)
Background: Basal cell carcinoma (BCC), the most common malignant tumor, accounts for 85%–95% of cases of eyelid malignant tumors. Demographic factors such as age, gender, tumor location, and subtype play a crucial role in epidemiological knowledge. We investigated eyelid BCC diagnosis and treatment at the Department of Ophthalmology in Centro Hospitalar de Setúbal (CHS). Methods: A retrospective study was conducted on patient cases with suspected eyelid epithelial tumors who underwent excisional biopsy surgery. The study included data from the CHS database between 2015 and 2021. Data collection and subsequent analysis were based on histopathological results. Results: In our study, were analyzed a total of 47 tumor cases, with 68.1% located on the lower eyelids and 31.9% on the upper eyelids. Among these cases, 25 (53.2%) were classified as benign, while 22 (46.8%) were identified as malignant eyelid tumors. BCCs accounted for 90.9% of all malignant cases, with an average age of 71.7 ± 16.6 years. The nodular subtype was the most prevalent, followed by infiltrative and superficial subtypes. Superficial BCC patients were older than infiltrative BCC patients (median age = 69.5 years vs. 61.5 years). BCC primarily affected the lower eyelids compared to the upper eyelid, and there was a slight female predominance (n = 11). All diagnosed BCCs correlated with sun-exposed regions. Conclusions: Timely intervention is crucial for reducing morbidity. These findings emphasize the need for improved registration and notification systems to enhance the prevention and treatment of eyelid BCCs. Furthermore, despite advancements in ultraviolet-blocking technologies, further development of sunscreen specifically formulated for ocular use remains necessary to reduce the incidence of eyelid tumors.
- Open Access
- 8 November 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 90
Development of an adhesive tablet for the delivery of Diospyros villosa root for the treatment of oral cavity diseases
- 8 November 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 90
Open AccessDevelopment of an adhesive tablet for the delivery of Diospyros villosa root for the treatment of oral cavity diseases
- 31 October 2023
- Published by Scientific Research and Community Ltd in Journal of Ophthalmology Research Reviews & Reports
- Vol. 4 (146) , 1-8
Are we Capable of Contributing to the Reduction of Eyelid Basal Cell Carcinoma? Building a Healthcare Team
Background: Basal cell carcinoma (BCC) is the most common malignant eyelid tumour encountered by oculoplastic surgeons (ophthalmologists), contributing significantly to morbidity. The objective of this study was to assess awareness levels and knowledge among healthcare professionals and the general public,regarding eyelid BCC, with a specific focus on the following areas: risk factors, prevention habits and pharmaceutical counseling. Methods: A cross-sectional survey study was employed for data collection. Anonymous surveys were distributed to two distinct groups: healthcare professionals (comprising physicians, pharmacists, and pharmacy students) and members of the general community in Setúbal. Data collection took place on a single day for each of these two groups. Results: The study encompassed 201 participants, consisting of 155 (77.1%) females (mean age = 42 years-old), and 44 (21.9%) males (mean age = 46 years-old). The survey revealed that 55.2% of respondents were unaware of the typical location of eyelid BCC. Furthermore, the majority of participants expressed consensus on the importance of applying sunscreen as a preventive measure. Conclusion: The study underscores the necessity for enhanced efforts in preventing eyelid BCC, emphasizing the crucial role of implementing protocols and educational initiatives targeting both healthcare professionals and the general public. These measures are essential to raise awareness, facilitate early detection, and enhance the management of eyelid BCC cases
- 31 October 2023
- Published by Scientific Research and Community Ltd in Journal of Ophthalmology Research Reviews & Reports
- Vol. 4 (146) , 1-8
Are we Capable of Contributing to the Reduction of Eyelid Basal Cell Carcinoma? Building a Healthcare Team
Background: Basal cell carcinoma (BCC) is the most common malignant eyelid tumour encountered by oculoplastic surgeons (ophthalmologists), contributing significantly to morbidity. The objective of this study was to assess awareness levels and knowledge among healthcare professionals and the general public,regarding eyelid BCC, with a specific focus on the following areas: risk factors, prevention habits and pharmaceutical counseling. Methods: A cross-sectional survey study was employed for data collection. Anonymous surveys were distributed to two distinct groups: healthcare professionals (comprising physicians, pharmacists, and pharmacy students) and members of the general community in Setúbal. Data collection took place on a single day for each of these two groups. Results: The study encompassed 201 participants, consisting of 155 (77.1%) females (mean age = 42 years-old), and 44 (21.9%) males (mean age = 46 years-old). The survey revealed that 55.2% of respondents were unaware of the typical location of eyelid BCC. Furthermore, the majority of participants expressed consensus on the importance of applying sunscreen as a preventive measure. Conclusion: The study underscores the necessity for enhanced efforts in preventing eyelid BCC, emphasizing the crucial role of implementing protocols and educational initiatives targeting both healthcare professionals and the general public. These measures are essential to raise awareness, facilitate early detection, and enhance the management of eyelid BCC cases
- Open Access
The Genus Diospyros: A Review of Novel Insights into the Biological Activity and Species of Mozambican Flora
Species of the Diospyros L. genus (Ebenaceae family) have been largely used in traditional medicine for the treatment of several diseases, especially infectious ones. To date, active major compounds such as naphthoquinones, triterpenoids, and tannins have been isolated and pharmacologically validated from Diospyros species. The present study summarizes the information available in the literature on the species described in the Flora of Mozambique. To do so, scientific databases (e.g., PubMed, Scopus, Web of Science, and Google Scholar) were searched using various keywords and Boolean connectors to gather and summarize the information. Of the 31 native and naturalized species in the Flora of Mozambique, 17 are used in different regions of Africa and were described for their traditional uses. They were reported to treat more than 20 diseases, mostly infectious, in the gastrointestinal and oral cavity compartments. This work provides an overview of the therapeutical potential of Diospyros species and explores novel insights on the antimicrobial potential of extracts and/or isolated compounds of these Mozambican species.
Open AccessThe Genus Diospyros: A Review of Novel Insights into the Biological Activity and Species of Mozambican Flora
Species of the Diospyros L. genus (Ebenaceae family) have been largely used in traditional medicine for the treatment of several diseases, especially infectious ones. To date, active major compounds such as naphthoquinones, triterpenoids, and tannins have been isolated and pharmacologically validated from Diospyros species. The present study summarizes the information available in the literature on the species described in the Flora of Mozambique. To do so, scientific databases (e.g., PubMed, Scopus, Web of Science, and Google Scholar) were searched using various keywords and Boolean connectors to gather and summarize the information. Of the 31 native and naturalized species in the Flora of Mozambique, 17 are used in different regions of Africa and were described for their traditional uses. They were reported to treat more than 20 diseases, mostly infectious, in the gastrointestinal and oral cavity compartments. This work provides an overview of the therapeutical potential of Diospyros species and explores novel insights on the antimicrobial potential of extracts and/or isolated compounds of these Mozambican species.
- Open Access
Diospyros villosa Root Monographic Quality Studies
Diospyros villosa L. (De Winter) (Ebenaceae) is a shrub whose root (DVR) is used as a toothbrush and to treat oral infections in Mozambique. The present work aims at establishing monographic quality criteria to allow the sustainable and safe development of pharmaceutical preparations with this herbal drug. This includes setting botanical (qualitative and quantitative) and chemical identification parameters, purity tests (loss on drying and total ash), quantifying the major classes of constituents identified, and particle size characterization of the powdered drug. DVR samples are cylindrical and microscopically characterized by: a periderm, with six layers of flattened phellem cells, with slightly thickened walls and few layers of phelloderm; cortical parenchyma with brachysclereids with a short, roughly isodiametric form (13.82–442.14 μm2 × 103), surrounded by a ring of prismatic calcium oxalate crystals; uniseriate medullary rays and prominent vessels of the xylem with single or double shape; numerous single and clustered starch grains, within the cortical parenchyma, medullar parenchyma, and ray cells. Polyphenols, mainly hydrolyzable tannins (212.29 ± 0.005 mg gallic acid equivalent/g of dried DVR), are the main marker class of constituents. Furthermore, the average diameter of the particles of the powder, 0.255 mm, allows its classification as a fine powder.
Open AccessDiospyros villosa Root Monographic Quality Studies
Diospyros villosa L. (De Winter) (Ebenaceae) is a shrub whose root (DVR) is used as a toothbrush and to treat oral infections in Mozambique. The present work aims at establishing monographic quality criteria to allow the sustainable and safe development of pharmaceutical preparations with this herbal drug. This includes setting botanical (qualitative and quantitative) and chemical identification parameters, purity tests (loss on drying and total ash), quantifying the major classes of constituents identified, and particle size characterization of the powdered drug. DVR samples are cylindrical and microscopically characterized by: a periderm, with six layers of flattened phellem cells, with slightly thickened walls and few layers of phelloderm; cortical parenchyma with brachysclereids with a short, roughly isodiametric form (13.82–442.14 μm2 × 103), surrounded by a ring of prismatic calcium oxalate crystals; uniseriate medullary rays and prominent vessels of the xylem with single or double shape; numerous single and clustered starch grains, within the cortical parenchyma, medullar parenchyma, and ray cells. Polyphenols, mainly hydrolyzable tannins (212.29 ± 0.005 mg gallic acid equivalent/g of dried DVR), are the main marker class of constituents. Furthermore, the average diameter of the particles of the powder, 0.255 mm, allows its classification as a fine powder.